Item 9 Labs Corp (INLB) fair value: what the stock is really worth
We calculate from audited financials what Item 9 Labs Corp is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 29, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Item 9 Labs Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0001 – $4.00 · the $0.0001 price screens below the $0.0001 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 29, 2026.
Follow Item 9 Labs in your weekly email
Every Wednesday you see whether Item 9 Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware.
Show more
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.
Stock analysis
Item 9 Labs Corp (INLB) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 5/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Item 9 Labs Corp reported revenue of $21.8M in FY2022 versus $1.4M in FY2018, a compound +99.4%/yr. Reported net income was −$31.1M in FY2022.
Key figures
Market cap $9.6K · EPS (TTM) $−0.3300 · Net margin −143% · Return on equity −47.4% · Return on assets (EBIT) −20.3% · Operating margin −55.7% · Revenue (TTM) $19.7M · Revenue growth (YoY) +1.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 0%, INLB screens cheaper than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+145.5%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.6%
’12
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−187.0% (2016) → −106.0% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Item 9 Labs Corp (INLB) overvalued or undervalued?
As of Jul 29, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 18, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of INLB?
Our model-based fair value for Item 9 Labs Corp is $0.0001 (as of Jul 29, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.0001.
What is the quality score of INLB?
Item 9 Labs Corp has a Quality Score of 5/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Item 9 Labs Corp (INLB)?
Our model-based price target is the fair value of $0.0001 (as of Jul 29, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Item 9 Labs Corp stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 18, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Item 9 Labs Corp (INLB)?
Item 9 Labs Corp reported trailing-twelve-month revenue of about $19.7M (latest available figure, as of Jul 29, 2026).
What is the intrinsic value of Item 9 Labs Corp (INLB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Item 9 Labs Corp it is $0.0001 per share (as of Jul 29, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Item 9 Labs Corp stock overvalued or undervalued in 2026?
As of Jul 29, 2026, INLB trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INLB?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Item 9 Labs Corp the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Item 9 Labs Corp worth?
The market values Item 9 Labs Corp at about $9.6K (market capitalisation, as of Jul 29, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Item 9 Labs Corp (INLB)?
Balance-sheet figures for Item 9 Labs Corp (as of Jul 29, 2026): return on equity −47.4%, debt of 0.12 per unit of equity. They feed the Quality Score of 5/100, which measures business quality independently of the share price.
How far is INLB from its 52-week high?
Item 9 Labs Corp trades at $0.0001, at its 52-week high of $0.0001 and at the low of $0.0001 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Item 9 Labs Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Item 9 Labs Corp stock attractive at the current price?
The data as of Jul 29, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 5/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INLB calculated?
We run Item 9 Labs Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Item 9 Labs Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Item 9 Labs Corp (INLB)?
The latest price we hold is from Sep 18, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Item 9 Labs Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Item 9 Labs Corp
How large is the market capitalisation of Item 9 Labs Corp (INLB)?
The market capitalisation of Item 9 Labs Corp is $9.6K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Item 9 Labs Corp (INLB)?
Earnings per share at Item 9 Labs Corp are $−0.3300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Item 9 Labs Corp (INLB)?
The net margin of Item 9 Labs Corp is −143% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Item 9 Labs Corp (INLB)?
The return on equity (ROE) of Item 9 Labs Corp is −47.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Item 9 Labs Corp (INLB)?
On an EBIT basis the return on assets of Item 9 Labs Corp is −20.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Item 9 Labs Corp (INLB)?
The operating margin of Item 9 Labs Corp is −55.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Item 9 Labs Corp (INLB)?
Revenue at Item 9 Labs Corp is growing +1.8% versus a year earlier (3y avg +64.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Item 9 Labs Corp (INLB) generate?
The free cash flow of Item 9 Labs Corp is −$7.7M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Item 9 Labs Corp (INLB) carry?
The net debt of Item 9 Labs Corp is $27.8M (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Item 9 Labs Corp in the live analysis
One click puts Item 9 Labs Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jul 29, 2026